Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This project uses both transcriptomic- and genomic-level data to identify mechanisms of
individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with
prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss,
cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will
illuminate causal links between disease genotype and phenotype, which may ultimately guide
personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular
disease, renal disease, and other related diseases.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston